Sanofi is ploughing ahead with a broad Phase III development program for its oral SERD (selective estrogen receptor degrader) candidate amcenestrant ahead of a key first Phase III readout this year, while the firm and its closest rivals released more early clinical data at the recent American Society of Clinical Oncology meeting (ASCO) that give hints at the marketing contest to come.
Sanofi’s amcenestrant is the most advanced of the oral SERD candidates and the French major is expanding its development program for the product into earlier treatment